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If an imprinted region is involved, the same genomic
change can lead to a different phenotype depending on
the parental origin of the defect. Prader-Willi syndrome
and Angelman syndrome are good examples. In these
situations, some genes on chromosome 15q normally
show preferential expression from the maternal allele
and others from the paternal allele. A large deletion in
this region, for example, would result in loss of expression
of different genes depending on its parental origin, thereby
explaining the two disparate phenotypes. Garfield et al.
recently provide evidence in mice that disruption of a
single imprinted gene can have a different effect depend-
ing on its origin. With imprinted genes, the expression
bias is usually focused toward one parental allele, although
this bias may be restricted to certain tissues. In contrast,
the two parental alleles of Grb10 have opposing expres-
sion; in most embryonic tissues, the maternal allele is
expressed, but it is the paternal allele that is selectively
expressed in the central nervous system. Garfield et al.
recently generated a Grb10 knockout allele in mice and
transmitted it from males and from females to discern
the function of each parental allele. They find that the
two parental alleles of Grb10 have evolved different func-
tions in different tissues. Whereas the maternal allele is
a regulator of growth, the paternal allele regulates social
behavior. Loss of the paternal allele gave rise to mice that
were more socially dominant, including excessive facial
barbering of their cage-mates. I guess sometimes the battle
of the sexes can be found within.
Garfield et al. (2011). Nature 469, 534–538. 10.1038/
nature09651.
Deciphering the Functional Role of Intergenic
Variation
One of the most replicated genetic associations for coro-
nary artery disease (CAD) is with markers at chromosome
9p21, but the markers happen to lie within a gene desert.
This fact, coupled with the extensive linkage disequilib-
rium in the region, has made it daunting to tease apart
the functional role of the region in CAD. To tackle this,
Harismendy et al. identified likely regulatory elements in
the region through examinations of transcription factor
binding and chromatin modification profiles. They then
tried tomatch these regulatory elements with the potential
functional sequence variation in the region, focusing on1Department of Human Genetics, Emory University School of Medicine, Atlan
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The Ameria predicted IFN-g-regulated STAT1 transcription factor
binding site that is disrupted by the CAD risk haplotype.
By using amodified chromatin conformation capture tech-
nique, they were able to define long-distance interactions
with this enhancer site and show that they are influenced
by IFN-g. In addition to implicating this inflammatory
signaling response inCAD, this work could serve as amodel
for the identification of the functional role of intergenic
variation identified through genetic association studies.
Harismendy et al. (2011). Nature 470, 264–268. 10.1038/
nature09753.
MicroRNA-Mediated Regulation of BRCA1
Although BRCA1 mutations are one of the most common
causes of inherited breast cancer syndrome, mutations in
this gene seem to be rare in sporadic breast tumors. At
the same time, reduced BRCA1 expression is observed in
a significant fraction of sporadic breast tumors, and only
a minority of this reduced expression can be explained
by BRCA1 promoter methylation. This led Moskwa et al.
to look for another mechanism that could explain downre-
gulation of BRCA1 expression in sporadic tumors, and they
focused on the identification of regulatory microRNAs.
Their results suggest a role for miR-182 in the regulation
of BRCA1 expression: cells that express high relative levels
of miR-182 express less BRCA1 and have reduced homolo-
gous recombination-mediated double-strand break repair.
Attempts are being made to exploit this type of DNA repair
deficiency for the treatment of BRCA mutation-associated
breast tumors by inhibition of PARP, which creates a
synthetic lethality. The work on miR-182 suggests that
PARP inhibitors might also have relevance for certain
sporadic breast tumors because in both tissue culture
and xenograft models, breast tumors that overexpress
miR-182 show increased sensitivity to PARP1 inhibitors.
Moskwa et al. (2011). Mol. Cell 41, 210–220. 10.1016/
j.molcel.2010.12.005.
Inherited and Somatic Ion Channel Mutations
Cause Hypertension
In up to 1 in 10 cases of essential hypertension, the under-
lying cause turns out to be an aldosterone-producing
adrenal adenoma (APA). This generally benign tumor
causes the adrenal gland to produce the hormone aldoste-
rone in the absence of the normal signals, leading to hyper-
tension and low potassium levels in the blood. Choi et al.ta, GA 30322, USA
Genetics. All rights reserved.
can Journal of Human Genetics 88, 251–252, March 11, 2011 251
uncovered an underlying genetic cause of APA that furthers
our understanding of the development of these tumors.
Their discovery was made through exome sequencing of
matched blood and tumor samples. Two of the four tumor
samples had a mutation in the same gene, KCNJ5, that
was not present in the matched blood sample. KCNJ5
sequencing in additional APA samples found that the
same twomutations in this gene account for 8of 22 samples
overall. Both mutations are found near the selectivity filter
of this Kþ channel and appear to lead to loss of channel
selectivity and influx of Naþ through the channel. The
authors believe that the resulting chronic depolarization
activates voltage-gatedCa2þ channels in cells in the adrenal
gland, and the resulting increase in intracellular Ca2þ levels
increases aldosterone synthesis as well as cell proliferation.
This idea is borne out by the identification of an inherited
KCNJ5 mutation that, as a result of its presence in all cells
in the adrenal gland, leads to massive hyperplasia of the
whole gland rather than tumor formation. The inherited
mutation was uncovered in a man and his two daughters
who, in addition to aldosteronism,had severehypertension
diagnosed in childhood.
Choi et al. (2011). Science 331, 768–772. 10.1126/
science.1198785; J.W. Funder (2011). Science 331, 685–686.
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Amidst all the hoopla over the ten-year anniversary of the
publication of the human genome come reminders that
high-throughput genetic analysis can sometimes uncover
things that we don’t want to know. Two recent articles
consider the duties of research and diagnostic labs to reveal
these unexpected results. Schaaf et al. discuss the possibility
of discovering incestuous relationships via SNP-based DNA
microarrays that uncover an absence of heterozygosity over
large portions of the genome. Jennifer Couzin-Frankel
talked to several geneticists to get their views on the duty
to disclose a variety of underlying genetic risk factors that
weren’t central to the original genetic test or research study.
As more genomes and exomes are sequenced, this will
certainly become an increasing problem. Do you stick to
notifying only those individuals with risks that have a tar-
geted intervention? Does the increased risk have to be
above a certain level? Do you have to confirm the result in
a CLIA-certified lab before they are disclosed? Both papers
urge laboratory directors to be forward thinking on policy
development toward what they will disclose and how this
disclosure should be made.
Schaaf et al. (2011). Lancet 377, 555–556. 10.1016/S0140-
6736(11)60201-8; J. Couzin-Frankel (2011). Science 331,
662–665. 10.1126/science.331.6018.662.This Month in Our Sister JournalsIndividual Patient Management Directed
by Whole-Exome Sequence
Whole-exome sequencing is all the rage right now for the
identification of disease genes, but it usually requires
multiple affected individuals in order to pull the true, caus-
ative mutation from the huge pile of sequence variation.
Worthey et al. provide a recent example in which they
were able to diagnose and alter treatment for a young boy
based on his exome sequence alone. The boy presented
with an extremely severe form of inflammatory bowel
disease that was quite intractable to management. The
authors expected that there was an underlying immune
deficiency, but single-gene sequencing had yielded no
underlying explanation. Despite increasing levels of inter-
vention, the boy’s condition continued to worsen, so
whole-exome sequencing was performed with the hope
that it would provide guidance on patient management.A mutation was found in the X-linked gene XIAP, which
was not even among the top 2000 candidate genes that
theauthorsproposedbefore theexome sequencewasgener-
ated. XIAP had not been linked to inflammatory bowel
disease before, but it does play a role in the immune
response.More importantly for thepatient,XIAPdeficiency
carries a high risk of death from hemophagocytic lympho-
histiocytosis (HLH), the suggested treatment for which is
hematopoietic progenitor cell transplantation. Although
it was not known whether this would have any effect on
his bowel disease, the risk ofHLH itself justified a transplant
in the child, and it turned out that the bowel disease did
respond. Posttransplant, he can now eat a variety of foods
and has not had recurrence of his bowel disease. Who says
the human genome project hasn’t done anything?
Worthey et al. (2010). Genet. Med. Published online
December 17, 2010. 10.1097/GIM.0b013e3182088158.1, 2011
